NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

SELLAS Life Sciences Group, Inc. (SLS) Stock Analysis

SELLAS Life Sciences Group, Inc. (SLS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SLS

$12.14

+$0.16 (+1.34%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLS with… →

SLS Key Statistics

As of Oct 21, 2026
Trading
Open
$12.07
Previous Close
$11.98
Day's Range
11.81–12.34
52-Week Range
1.39–15.88
Volume
5.64M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.57
Valuation
Market Cap
$2.45B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.21
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.86M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
201.95M
1-Year Return
+535.60%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
6.49M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SLS closed at $12.14, +535.60% over 1 year.

SELLAS Life Sciences Group, Inc. (SLS) has a market capitalization of $2.45B.

In fiscal 2025, SLS reported revenue of $0.00.

SLS Stock Return by Calendar Year

SELLAS Life Sciences Group, Inc. (SLS) 10-year return: what $10,000 became

1 year
$10,000 $63,560
+535.60%
5 years
$10,000 $13,400
+34.00%
10 years
$10,000 $14
−99.86%

If you had invested $10,000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, at the close on October 21, 2016, it would have been worth $14 at the close on October 21, 2026: −99.86% in total, −48.00% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+222.02%
2025+262.50%
2024−1.89%
2023−55.08%
2022−57.32%
2021−4.82%
2020+35.12%
2019−93.01%
2018−84.23%
2017−86.60%
2016 (partial year)−80.20%

As of October 21, 2026.

SLS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.86M—
2024$0.00−$30.88M—
2023$0.00−$37.34M—
2022$1.00M−$41.30M−4,130.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$28.27M−$26.86M—
2024$0.00—−$31.51M−$30.88M—
2023$0.00$0.00−$37.87M−$37.34M—
2022$1.00M$900.00K−$31.95M−$41.30M−4,130.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

SELLAS Life Sciences Group, Inc. (SLS) carries a market capitalisation of $2.45B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 13.

SLS last closed at $12.14 on October 21, 2026. That is +$0.16 (+1.34%) against the previous close. Over the past 52 weeks the price has ranged from $1.39 to $15.88. The latest close sits 773.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $26.86M. Earnings per share on a trailing basis come to −0.21.

Across the 4 fiscal years on file, revenue moves from $1.00M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 2.57. Daily returns over the trailing 10 years annualize to a volatility of 128.31%. Over the trailing twelve months the total return is +535.60%. Measured over 10 years, that is −48.00% a year compounded.

Growth & Income

No dividend is on file for SLS.

So far in 2026 the total return is +222.02%. Across the complete calendar years on file, 2025 returned +262.50% and 2019 returned −93.01%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

SELLAS Life Sciences Group, Inc. (SLS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SELLAS Life Sciences Group, Inc. SLS $2.45B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. SELLAS Life Sciences Group, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Visit website →